Skip to main content

Table 4 Paired t tests for the change in log(CD8+) and the log(CD8+/CD4+)

From: A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

Group

Variable CI t

n complete both

Mean difference

p value t test

Overall

Tumor log(CD8)

[− 0.63, 0.12]

tumor.CD8

13

− 0.256

0.16

Tumor log(CD8/CD4)

[− 0.37, 0.48]

tumor.CD8.CD4

13

0.054

0.79

Aza

Tumor log(CD8)

[− 1.28, 1.02]

tumor.CD8

4

− 0.13

0.74

Tumor log(CD8/CD4)

[− 0.68, 0.91]

tumor.CD8.CD4

4

0.112

0.68

Rom

Tumor log(CD8)

[− 1.35, 0.16]

tumor.CD8

5

− 0.596

0.09

Tumor log(CD8/CD4)

[− 1.47, 1.11]

tumor.CD8.CD4

5

− 0.181

0.72

Aza + Rom

Tumor log(CD8)

[− 0.62, 0.70]

tumor.CD8

4

0.043

0.85

Tumor log(CD8/CD4)

[− 0.30, 0.88]

tumor.CD8.CD4

4

0.289

0.22

  1. Aza azacitidine plus pembrolizumab (Arm A), Rom romidepsin plus pembrolizumab (arm B), Aza + Rom azacitidine plus romidepsin plus pembrolizumab (Arm C)